mk 0663 has been researched along with Cholera Infantum in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (75.00) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boyce, S; Brideau, C; Chan, CC; Charleson, S; Dubé, D; Ethier, D; Falgueyret, JP; Ford-Hutchinson, AW; Friesen, RW; Girard, Y; Gordon, R; Greig, G; Gresser, M; Guay, J; Mancini, J; Ouellet, M; Percival, MD; Prasit, P; Riendeau, D; Rodger, IW; Visco, D; Wong, E; Xu, L; Young, RN; Zamboni, R | 1 |
| Cannon, CP; Combe, B; Connors, L; Curtis, S; Emery, P; Kaur, A; Laine, L; McCarthy, T; McLay, J; Swergold, G; Zerbini, C | 1 |
| Chang, FY; Chen, TS; Hsiang, KW; Lee, KC; Lee, SD; Lin, HC; Lin, HY; Lu, CL; Luo, JC | 1 |
| Alekseeva, LI | 1 |
| Cannon, CP; Cryer, B; Curtis, SP; Kaur, A; Laine, L | 2 |
| Lories, RJ | 1 |
| Capell, HA; Duncan, MR | 1 |
| Crespi, S; Hunsche, E; Moore, A; Pellissier, J; Phillips, C | 1 |
| Benoit, V; de Leval, X; Dogné, JM; Frederich, M; Julémont, F; Pirotte, B | 1 |
| Choi, YS; Kim, JA; Kim, SH | 1 |
| Bingham, CO; Bird, S; Fitzgerald, BJ; Kremer, J; O'Brien, K; Rubin, BR; Ruoff, GE; Sebba, AI; Smugar, SS; Tershakovec, AM | 1 |
| Bergman, G; Curtis, SP; Ko, AT; Malmstrom, K; Mehta, A; Reginster, JY; Reicin, AS | 1 |
| Baraf, HS; Bird, S; Brzezicki, J; Curtis, SP; Fuentealba, C; Greenwald, M; Kaur, A; O'Brien, K; Polis, A; Soffer, B | 1 |
| Einecke, D | 1 |
| Curtis, S; Dore, R; Kaur, A; Krueger, K; Lino, L; Radominski, S; Simpson, R; Zhang, Y | 1 |
4 review(s) available for mk 0663 and Cholera Infantum
| Article | Year |
|---|---|
[Comparative evaluation of the safety and efficacy of etoricoxib and diclofenac on the upper gastrointestinal tract in patients with osteoarthrosis and rheumatoid arthritis (the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study pro
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Etoricoxib; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Osteoarthritis; Pyridines; Randomized Controlled Trials as Topic; Sulfones; Treatment Outcome | 2010 |
Etoricoxib and the treatment of ankylosing spondylitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Etoricoxib; Gastrointestinal Diseases; Half-Life; Humans; Pain; Pyridines; Spondylitis, Ankylosing; Sulfones | 2012 |
First and second generations of COX-2 selective inhibitors.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2004 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Female; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Osteoarthritis; Peptic Ulcer; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Pyridines; Sulfones | 2007 |
6 trial(s) available for mk 0663 and Cholera Infantum
| Article | Year |
|---|---|
Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study).
Topics: Aged; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Emergencies; Etoricoxib; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Odds Ratio; Osteoarthritis; Pyridines; Safety; Sample Size; Sulfones; Thrombosis | 2009 |
Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyridines; Risk Factors; Sulfones; Time Factors; Upper Gastrointestinal Tract | 2010 |
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Etoricoxib; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Male; Middle Aged; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Pyrazoles; Pyridines; Severity of Illness Index; Sulfonamides; Sulfones; Thrombosis; Treatment Outcome | 2007 |
Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Naproxen; Osteoarthritis; Pain Measurement; Pyridines; Sulfones; Time Factors; Treatment Outcome | 2007 |
Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Etoricoxib; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Osteoarthritis; Pyridines; Sulfones; Treatment Outcome; Withholding Treatment | 2007 |
Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Etoricoxib; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Pyridines; Sulfones; Treatment Outcome | 2008 |
6 other study(ies) available for mk 0663 and Cholera Infantum
| Article | Year |
|---|---|
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
Topics: Algorithms; Animals; Anti-Inflammatory Agents; Arachidonic Acid; CHO Cells; Cricetinae; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Gastrointestinal Diseases; Humans; Ionophores; Isoenzymes; Male; Membrane Proteins; Microsomes, Liver; Prostaglandin-Endoperoxide Synthases; Pyridines; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Substrate Specificity; Sulfones; Thromboxane B2 | 2001 |
Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Etoricoxib; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Incidence; Logistic Models; Male; Middle Aged; Multivariate Analysis; Peptic Ulcer; Prospective Studies; Pyrazoles; Pyridines; Risk Factors; Sulfonamides; Sulfones; Taiwan | 2010 |
Etoricoxib in the treatment of chronic pain.
Topics: Adult; Aged; Arthritis; Cardiovascular Diseases; Chronic Disease; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Gastrointestinal Diseases; Humans; Low Back Pain; Middle Aged; Pain; Pyridines; Randomized Controlled Trials as Topic; Sulfones | 2003 |
Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Etoricoxib; Gastrointestinal Diseases; Histamine H2 Antagonists; Humans; Middle Aged; Misoprostol; Models, Economic; Osteoarthritis; Proton Pump Inhibitors; Pyridines; Quality-Adjusted Life Years; Risk; Sulfones; Time Factors; United Kingdom | 2004 |
Adverse effects of etoricoxib: other considerations.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etoricoxib; Gastrointestinal Diseases; Humans; Osteoarthritis; Pyridines; Sulfones | 2005 |
[By what means does the rheumatic patient with gastrointestinal risks fare best?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Controlled Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Gastrointestinal Diseases; Germany; Humans; Naproxen; Osteoarthritis; Proton Pump Inhibitors; Pyridines; Rheumatic Diseases; Risk Factors; Sulfones; United States | 2007 |